- The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC:IVBXF) and Eli Lilly And Co's (NYSE:LLY) Tyvyt (sintilimab injection) in non-small cell lung cancer (NSCLC).
- The approval is for expanded use of Tyvyt in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC).
- It is the third NMPA-approved indication of Tyvyt, following the approval in December 2018 for relapsed or refractory classical Hodgkin's lymphoma, and the approval in February 2021 for the first-line treatment of non-squamous non-small cell lung cancer.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: LLY shares closed at $199.13 on Wednesday.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
